GLP-1 or HRT After 40? Why Chattanooga Patients Need Both

> Editorial note (Calliope → Paul): the middle section names a mechanistic interaction between GLP-1 central appetite signaling and perimenopause/andropause hypothalamic-pituitary changes. That connection is framed in-text as my clinical synthesis, not a cited trial finding — please verify/adjust the wording before this goes live per your own clinical judgment.

I’ve had patients drive in from Ooltewah and Signal Mountain after doing everything right on a GLP-1 — hitting their dose, tracking protein, showing up to every appointment — and still hit a wall. They ask me the same question every time: why did this stop working? Here in Chattanooga, that question sends most people back to Google, typing some version of “GLP-1 or hormone therapy, which one do I actually need.” I’m the board-certified physician in this city running both as one service line, not two separate referrals — so I’m going to give you the real answer, not a pitch for either drug class.

The GLP-1 pitch you see on social media treats appetite like a single dial: turn it down, weight comes off. Semaglutide and tirzepatide do turn that dial — they work centrally, binding receptors in the hypothalamus that govern appetite and satiety signaling. For a lot of patients, that’s the whole story, and it works well.

But after 40, that same hypothalamic-pituitary circuitry has another job. It’s also part of the control system for reproductive hormone signaling. Perimenopause and andropause don’t happen in some separate system — they happen in the same neuroendocrine neighborhood the GLP-1 is trying to work in.

Here’s the honest part, and it’s mine, not a trial’s: I think that overlap is a real reason so many patients over 40 do everything right on a GLP-1 and still plateau, feel flat, or watch muscle disappear along with fat. Call it a plausible mechanistic interaction based on where these two systems sit — not a proven combined-therapy outcome. I won’t oversell it as more than that. But I’ve watched the pattern often enough in my own exam room to stop assuming appetite suppression was the only variable at play.

GLP-1 medications fix an appetite and satiety problem. In STEP 1 (NEJM, 2021), semaglutide produced a mean body-weight reduction of about 14.9% at 68 weeks. In SURMOUNT-1 (NEJM, 2022), tirzepatide reached up to 20.9% at 72 weeks on the highest dose. Those are real numbers — and they’re group averages from clinical trials, not a promise about you.

What GLP-1s don’t touch: declining testosterone in men, and the estrogen and progesterone shifts of perimenopause in women. Those changes drive their own separate list of symptoms — energy, sleep, mood, muscle retention, and yes, weight distribution. No amount of appetite suppression corrects a genuine hormone deficiency, because it was never targeting hormones in the first place.

That’s why “just take the shot” is half an answer for a 47-year-old woman in perimenopause or a 52-year-old man with low testosterone. It treats the appetite side and leaves the hormone side exactly where it was.

STEP 1 and SURMOUNT-1 are the trials every GLP-1 ad quotes, and they’re legitimate, well-run studies. Read past the headline number, though: they weren’t designed to isolate what happens when a 68- to 72-week appetite intervention runs on top of an already-shifting hormone environment. Hormone status wasn’t the variable those trials were built to track.

That’s not a knock on the trials. It’s a gap between what they measured and what a 40-plus patient actually walks in with. And it’s exactly the gap a patient falls into when a script queue hands them a dose and nothing else.

This is why I read trial data the way I read a chart — carefully, and with an eye for what wasn’t studied, not just what was. A drug can be genuinely effective in a trial and still be an incomplete answer for a specific patient sitting in front of me. Both things are true at once, and pretending otherwise is how patients end up plateaued for months before anyone asks the next question.

Ro, Hims/Hers, Found, and Henry Meds aren’t named here to take a shot for its own sake. They’re named because their entire model is structurally incapable of even asking the question this post answers. They’re NP- and PA-staffed script queues built to move volume on one drug class. There’s no hormone service line to route a patient to, no physician sitting across the intake reading labs for both systems at once.

That’s what I’m angry about with the DTC telehealth model — not that it exists, but that it cannot fix the exact problem it creates. A patient plateaus on their subscription, and the platform’s only lever is “raise the dose” or “switch GLP-1s.” Nobody on the other end is positioned to ask whether the real issue is hormonal. It isn’t a service they overlooked adding. It’s a business built on a checkout flow, not a chart.

At Summit, I personally review every chart — not a questionnaire run through software, not a nurse queue deciding your dose. When a patient over 40 comes in for weight, I’m looking at appetite regulation and hormone labs in the same visit, because I built the practice to run both as one integrated service line instead of two referrals you’d have to coordinate yourself.

That means real lab work before any hormone decision, GLP-1 dosing tailored to your tolerance, and a plan that treats the two systems as connected instead of coincidentally overlapping. If your labs don’t support HRT, I’ll tell you that too — the honest answer depends on what your own biology is doing, not on what’s easiest to sell.

A few patterns I see constantly in patients who’ve been GLP-1-only for months:

– Weight loss stalled well before goal, despite consistent dosing and diet – Persistent fatigue or a flat mood that started around when hormonal changes would be expected — mid-40s for many women, 50s for many men, earlier for some – Muscle loss that feels disproportionate to the fat lost – Sleep that got worse, not better, as weight came down

None of these prove a hormone problem on their own. But if more than one applies and nobody has run your hormone labs, you’re getting appetite management — not metabolic care.

If you’re over 40 and only one side of this equation has been addressed, that’s not a personal failure — it’s an incomplete plan. Chattanooga doesn’t have many places that will look at both systems in the same visit, run by the same physician, in a single chart. Summit does, because I built it that way on purpose — not because it’s the easier business model, but because it’s the one that actually answers the question you came here with.

Ready to start? Apply at summitmetabolichealth.com/apply

📞 (423) 407-7837 · ✉️ info@summitmetabolic.health 📍 200 W MLK Blvd Ste 1000, Chattanooga, TN 37402

This article is for general educational purposes only and is not medical advice. GLP-1 medications and hormone replacement therapy require evaluation, screening, and ongoing monitoring by a licensed physician. Individual results vary. Please consult Summit Metabolic Health or your own clinician before starting any treatment.